During Friday’s Current trade, Shares of Novo Nordisk A/S (ADR) (NYSE:NVO), lost -1.44% to $54.11.
Xybion Corporation declared that Novo Nordisk (NVO) has selected Xybion’s Pristima® Suite to manage all its non-GLP pharmacology studies in a global setting. The Pristima Suite is a preclinical software platform that offers a fully integrated, end-to-end enterprise solution for tracking and managing veterinary facilities and animal studies throughout the preclinical research process.
Xybion will provide a number of services and improvements to the Pristima platform to support non-GLP pharmacology studies, enabling Novo Nordisk to leverage the system for early drug discovery studies. In addition, Xybion will provide critical training and implementation services to configure Pristima and prepare the user community to meet Novo Nordisk best practices and reporting specifications.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals.
Shares of Trevena Inc (NASDAQ:TRVN), declined -0.10% to $9.68, during its current trading session.
Trevena, Inc. (TRVN), a clinical stage pharmaceutical company, declared the closing of its formerly declared underwritten public offering of 7,475,000 shares of its common stock, counting 975,000 shares sold following the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $9.75 per share. The gross proceeds from the offering were $72.9 million, before deducting customary underwriting discounts and commissions and offering expenses.
Jefferies LLC, Cowen and Company, LLC and Barclays Capital Inc. acted as joint book-running managers for the offering. JMP Securities LLC and Needham & Company, LLC acted as co-managers for the offering.
Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company’s central nervous system product pipeline comprises TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, which is in Phase II clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-opioid receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its central nervous system product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment-refractory migraine headaches.
Aon Plc (NYSE:AON), during its Friday’s current trading session decreased -1.65% to $87.09.
Impact Forecasting, Aon Benfield’s catastrophe model development team, recently launches the latest edition of its monthly Global Catastrophe Recap report, which evaluates the impact of the natural disaster events that occurred worldwide during July 2015. Aon Benfield is the global reinsurance intermediary and capital advisor of Aon plc (AON).
The report reveals that Typhoon Chan-hom tracked across much of the Western Pacific Ocean during the month, causing extensive damage in China, Japan’s Okinawa Island chain, South Korea, Taiwan and Guam, killing at least six people and injuring 30 others.
Total economic losses were estimated at more than USD1.6 billion, with China bearing the greatest impact; according to China’s Ministry of Civil Affairs, damage from Chan-hom had resulted in a CNY9.1 billion (USD1.5 billion) economic loss, mainly as a result of damage to agricultural interests and infrastructure.
Aon plc provides risk administration services, insurance and reinsurance brokerage, and human resource consulting and outsourcing services worldwide. It operates through two segments, Risk Solutions and HR Solutions. The Risk Solutions segment offers retail brokerage services, counting affinity products, managing general underwriting, placement, captive administration services, and data and analytics; risk administration solutions for property liability, general liability, professional liability, directors’ and officers’ liability, workers’ compensation, and various healthcare products; and health and benefits consulting services comprising structuring, funding, and administering employee benefit programs. This segment also provides advisory services to technology, financial services, agribusiness, aviation, construction, health care, energy, and other industries.
Finally, ReneSola Ltd. (ADR) (NYSE:SOL), gained 5.56%, to $1.14.
ReneSola Ltd (SOL), a leading brand and technology provider of energy-efficient products, recently declared that during the third quarter of 2015, the Company repurchased $36.0 million notional amount of its convertible notes due on March 15, 2018 with a put option on March 15, 2016. The Company has about $26.1 million in convertible bonds outstanding. During the third quarter, the Company also repurchased about 807,000 American depositary shares (“ADSs”) following its declaration on September 23, 2015 of the authorization by its Board of Directors of a share repurchase program of up to US$20 million in aggregate value of its outstanding ADSs within the next 12 months.
The Company might continue to repurchase its convertible bonds and American depositary shares from time to time, subject to market conditions and other planned considerations. Such purchases will be made in accordance with the applicable laws and subject to any required regulatory approvals.
ReneSola Ltd, through its auxiliaries, manufactures and sells various solar power products. It operates through two segments, Wafer, and Cell and Module. The company offers virgin polysilicon; mono crystalline and multi crystalline solar wafers; and photovoltaic cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
